ATARA BIOTHERAPEUTICS, INC. : Entry into a Material Definiti

ATARA BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

Item 1.01 Entry into a Material Definitive Agreement

As previously disclosed, on May 13, 2022, Atara Biotherapeutics, Inc. received written notice of termination from Bayer AG of... | August 8, 2022

Related Keywords

California , United States , South San Francisco , Ukraine , Kristin Yarema , Atara Biotherapeutics Inc , Company Senior Vice , Technology Transfer Agreement , Exchange Commission , Company To Bayer , Securities Exchange , Program Transfer Agreement The Termination , Company Quarterly Report On Form , Material Definitive , License Agreement , Program Transfer Agreement , Termination Agreement , Supply Agreement , Pharmacovigilance Agreement , Equality Agreement , Quarterly Report , Charles River Laboratories , Commercial Manufacturing Agreement , Corporate Strategy , Securities Exchange Act , Securities Act , Certain Officers , Compensatory Arrangements , Senior Vice President , Chief Commercial Officer , Executive Employment Agreement , Page Interactive Data File , Looking Statements This Current Report , San Francisco , Financial Condition , Edgar Online , Atara Biotherapeutics , Nc Stock Exchange , News , Information , Press Release , Item , Entry , Into , Material , Efinitive , Reviously , N , Bay , Tara , Eceived , Written , Notice , F , Termination , Rom , Player , G Atra Us0465131078 ,